Facts & Figures

Facts - Grünenthal Group worldwide

Year of Foundation: 1946

Corporate Officers:

  • Prof. Dr. Eric-Paul Pâques, Chief Executive Officer (CEO) Grünenthal Group
  • Sascha Becker, Chief Financial Officer (CFO)
  • Dott. Alberto Grua., Chief Commercial Officer (CCO) Europe, Australia, North America & Global Product Supply
  • Dr. Klaus D. Langner, Chief Scientific Officer (CSO)

Supervisory Board 2015: 5 members

International Presence 2015: 32 countries with affiliates in Europe, Latin America and USA, Production sites in 5 countries, headquarters Aachen, Germany

Top-Selling Products (Global Brands 2014):  Palexia®, Versatis®, Zaldiar®, Tramal®, Transtec®, Norspan®, INTAC®, Arcoxia®

Focused indication preferably covered by our current target audience in Europe and Latin America:

Europe

  • Pain 
  • Inflammation 
  • Movement/Bone disorders 
  • Perioperative care 
  • Neurology/Psychiatry
  • Cancer supportive care

Latin America

  • Pain 
  • Women's health 
  • Central Nervous System 
  • Comprehensive solutions based on customers’ needs

Pain and focused indication preferably covered by our current target audience in Research and Development:

Research & Development

  • Pain 
  • Inflammation (niches) 
  • Perioperative Care 
  • Niches and orphan drugs 
  • Cancer supportive care

Corporate Figures - Year 2014 & 2013

Corporate Figures in Mio € 2014 2013
Revenues 1.154 901
Revenue Growth vs. Previous Year 28% 7%
Revenues by Business Unit 1.154 901
  Europe 623 560
   Latin America 389 203
   North America 109 106
    Other 33 32
Research & Development Costs 232 248
    R&D Costs Ratio (R&D Costs / Revenues) 20% 27%
Operating EBITA 89 36
    Operating EBITA / Revenues (%) 8%  4%
Income before Taxes (IBT) 76 -54
   Income before Taxes / Revenues (%) 7% -6%
Equity Ratio (%) 60% 64%
Employees (annual average, headcount) ca. 5,400 ca. 4,400

Our financial statements are published at www.bundesanzeiger.de (German)